Leishmaniasis in otorhinolaryngology: an emerging disease and its relationship with anti-tumor necrosis factor-alpha drugs

Eur Arch Otorhinolaryngol. 2024 May;281(5):2739-2742. doi: 10.1007/s00405-024-08569-1. Epub 2024 Mar 8.

Abstract

Purpose: To investigate the clinical manifestations, management and outcomes of Leishmania lesions in the ear-nose-throat (ENT) region, and its relationship with tumor necrosis factor (TNF)-α blocking drugs.

Methods: Single-center retrospective observational study. Patients diagnosed with cutaneous and mucosal leishmaniasis in the otorhinolaryngologic area at a tertiary referral center over a period of 8 years.

Results: Three cases of Leishmania lesions in the ear and two in the nose were encountered at our institution. All patients were under treatment with TNF-α blocking drugs. Diagnosis was challenging, and it was important to have a clinical suspicion in order to use accurate detection techniques. All patients received systemic treatment and achieved a complete resolution of the lesions.

Conclusions: With the increasing use of biologic treatments like TNF-α blockers, this type of infection will be increasingly frequent in endemic areas and also worldwide. It is important to include leishmaniasis in the differential diagnosis of inflammatory/infectious lesions in the ENT region.

Keywords: Anti-TNF alpha; Emerging disease; Leishmania; Leishmaniasis; Otorhinolaryngology.

Publication types

  • Observational Study

MeSH terms

  • Humans
  • Leishmaniasis* / diagnosis
  • Leishmaniasis* / drug therapy
  • Leishmaniasis, Cutaneous* / therapy
  • Otolaryngology*
  • Retrospective Studies
  • Skin
  • Tumor Necrosis Factor-alpha

Substances

  • Tumor Necrosis Factor-alpha